Olema Pharmaceuticals (OLMA) catalysts

Upcoming FDA decisions and readouts we track for Olema Pharmaceuticals, each with the filing that announced it.

Listed on — Nasdaq Catalysts tracked — 1 Rows last checked — 12 Sep 2026

FreeBioList tracks 1 upcoming catalyst for Olema Pharmaceuticals (OLMA, listed on Nasdaq). It concerns Palazestrant (OP-1250) (ER+/HER2- advanced breast cancer, 2nd/3rd line).

First on the list: the Phase 3 readout for Palazestrant (OP-1250) (ER+/HER2- advanced breast cancer, 2nd/3rd line), guided by the company to Q1 2027.

The row links to an SEC filing (8-K or 6-K). It has been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.

Background reading: How to read a Phase 3 topline readout.

Ticker: OLMA
Next catalyst: Q1 2027
Type: Phase 3 readout
Listed options: Yes

Company ▾	Drug ▾	Effect / indication	Next catalyst ▾	Phase / type ▾	Status ▾	Source	Options
Olema Pharmaceuticals OLMA · Nasdaq	Palazestrant (OP-1250)	ER+/HER2- advanced breast cancer, 2nd/3rd line	Q1 2027 company guidance	Phase 3 readout	Verified	8-K exhibit 99.1 ↗	Yes
Notes — Filing states the company will "Report top-line data from the pivotal Phase 3 OPERA-01 trial in the first quarter of 2027." Source: 8-K exhibit 99.1, filed 10 Aug 2026 · verified 12 Sep 2026

Companies working on related conditions

Context Therapeutics (CNTX)Platinum-resistant ovarian cancer (Claudin 6 x CD3); Urothelial, colorectal and triple-negative breast cancer (Nectin-4 x CD3)
Faeth Therapeutics (FTH)Endometrial cancer; HR-positive breast cancer
Jazz Pharmaceuticals (JAZZ)HER2-positive first-line gastroesophageal adenocarcinoma

Also due in Q1 2027

Cartesian Therapeutics (RNAC)Phase 3 readout for Descartes-08, Q1 2027
Annovis Bio (ANVS)Phase 3 readout for Buntanetap, Q1 2027
Ocugen (OCGN)Phase 3 readout for OCU400, Q1 2027
Atea Pharmaceuticals (AVIR)Phase 3 readout for Bemnifosbuvir + ruzasvir, Q1 2027
Stoke Therapeutics (STOK)Regulatory submission for Zorevunersen, Q1 2027
Intellia Therapeutics (NTLA)PDUFA date for Lonvoguran ziclumeran (lonvo-z), 10 Mar 2027